Home/ Stocks/ AVXL

Anavex Life Sciences

AVXL XNAS

$3.22 +0.17 (+5.45%) ▲ 15-min delayed

Open

$3.12

High

$3.25

Low

$3.12

Volume

735.5K

Market Cap

$298.40M

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 34 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$1.08M	$-5,681,000	$-0.06
FY 2025	$4.68M	$-46,377,000	$-0.54
Q3 2025	$1.07M	$-13,243,000	$-0.16
Q2 2025	$1.21M	$-11,196,000	$-0.13

Related Market News

No specific coverage for AVXL yet. Check out our latest market news or earnings calendar.

Get AVXL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Anavex Life Sciences.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.